Lynk Pharmaceuticals has entered into a commercialization collaboration with Simcere to jointly advance the development and commercialization of zemprocitinib across rheumatology (rheumatoid arthritis, ankylosing spondylitis) and dermatology indications.
PR Newswire news releases · 2026-11-06 12:30
View evidence
- CompanyPR Newswire news releases2026-11-06 12:30
Lynk Pharmaceuticals has entered into a commercialization collaboration with Simcere to jointly advance the development and commercialization of zemprocitinib across rheumatology (rheumatoid arthritis, ankylosing spondylitis) and dermatology indications.
View source